The estimated Net Worth of David S Kabakoff is at least $80.3 Milione dollars as of 17 June 2021. David Kabakoff owns over 30,000 units of Castle Biosciences stock worth over $15,625,994 and over the last 5 years he sold CSTL stock worth over $64,362,650. In addition, he makes $288,339 as Independent Director at Castle Biosciences.
David has made over 21 trades of the Castle Biosciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 30,000 units of CSTL stock worth $2,252,100 on 17 June 2021.
The largest trade he's ever made was selling 250,000 units of Castle Biosciences stock on 12 May 2020 worth over $8,625,000. On average, David trades about 48,017 units every 24 days since 2019. As of 17 June 2021 he still owns at least 503,577 units of Castle Biosciences stock.
You can see the complete history of David Kabakoff stock trades at the bottom of the page.
Dr. David S. Kabakoff Ph.D. serves as Independent Director of the Company. Since 2012, Dr. Kabakoff has served as a partner at HealthQuest Capital, an investment firm. Since 2007, Dr. Kabakoff has also served as an executive partner at Sofinnova Ventures, an investment firm. Dr. Kabakoff’s currently serves as chairman of the board of directors of NextCure, Inc., a publicly traded biopharmaceutical company. Dr. Kabakoff also serves on the board of directors of numerous private companies, including Antiva Biosciences, Inc., a biopharmaceutical company, Dauntless Pharmaceuticals, a biopharmaceutical company, Lineagen (chairman), a genetic testing company, bioTheranostics, a molecular diagnostics company, Rainier Therapeutics, Inc., a biopharmaceutical company and Neurana Pharmaceuticals, Inc., a biopharmaceutical company. From 2006 until October 2014, Dr. Kabakoff served on the board of directors of InterMune Inc., a publicly traded biopharmaceutical company. In 2001 Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drug treatments, served as its Chairman and Chief Executive Officer and led its acquisition in June 2005 by Cephalon, Inc. From 1996 to 2000, Dr. Kabakoff held the positions of Executive Vice President of Dura Pharmaceuticals, Inc. and President and Chief Executive Officer of Spiros, both pharmaceutical companies. From 1989 to 1996, Dr. Kabakoff was employed as Chief Executive Officer of Corvas International, Inc., a developer of biotherapeutics, and from 1983 to 1989 held senior executive positions with Hybritech, a biotechnology company. Dr. Kabakoff holds a B.A. degree in Chemistry from Case Western Reserve University and a Ph.D. from Yale University.
As the Independent Director of Castle Biosciences, the total compensation of David Kabakoff at Castle Biosciences is $288,339. There are 7 executives at Castle Biosciences getting paid more, with Derek Maetzold having the highest compensation of $4,132,350.
David Kabakoff is 72, he's been the Independent Director of Castle Biosciences since 2017. There are no older and 13 younger executives at Castle Biosciences.
David's mailing address filed with the SEC is C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD, 20705.
Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold e Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: